Linda Van Le, MD 
Professor of Obstetrics & Gynecology.
Division of Gynecologic Oncology.

Phone: (919) 966-5996
Fax: (919) 966-5670
E-Mail: lvl@med.unc.edu
Mailing Address: CB#7570, UNC-Chapel Hill
Chapel Hill, NC 27599-7570

Board Certifications                 
• Diplomate of American Board of Obstetrics
- & Gynecology, General Board Certification, 1989
• Recertified, 2000, 2001, 2002, 2003, 2004
• Diplomate of American Board of Obstetrics
- & Gynecology, Gynecologic Oncology
- Subspecialty, 1997

Professional Experience
• Assistant Professor of Ob/Gyn, University
- of Wisconsin, Milwaukee, 1987-1989
• Assistant Professor of Ob/Gyn, University
- of North Carolina, Chapel Hill, 1989-1996
• Associate Professor of Ob/Gyn, University of
- North Carolina, Chapel Hill, 1996-2002
• Professor of Ob/Gyn, University of North Carolina,
- Chapel Hill, 2002-present

Editorial Board
• Editorial Board, Obstetrics & Gynecology,
- 2000-2004
• Editor, Current Problems in Obstetrics
- Gynecology, & Infertility, 1999-2002
• Editorial Board, Gynecologic Oncology,
- 2003-present

Professional Societies and Memberships
• AmericanMid Atlantic Gynecologic Oncology Society - 2000
• American Association for Pharmaceutical Physicians - 2000 • Society for Gynecologic Investigation, 1995
• Society for Gynecologic Investigation - 1994
• American Society of Clinical Oncologists- 1994
• Society of Gynecologic Oncologists, 1993
• North Carolina Society of Obstetrics and Gynecology - ---- - 1993
• American Association for Cancer Research - 1993
• Robert A. Ross Society - 1993
• American College of Obstetricians and Gynecologists - - - - - 1990
• Society of Gynecologic Oncologists - 1989
• Association for - Cancer Research, 1992


Special Interests
• Chemotherapy trials and innovative treatment
- for ovarian cancer.

Research Focus
Dr. Van Le's primary research interests have focused on the description of new therapies for the treatment of ovarian cancer. She is director of the Gyn Oncology Chemotherapy clinic and has an interest in clinical trials.

Research & Grant Awards
1. “Role of Lysophosphatidic acid in the Diagnosis and Treatment of Ovarian Cancer “ Co PI with Dr. Andrew Morris, Lineberger Cancer Center Translational Award 2002, $35,000.

2. “Lysophospholipids mediators in Ovarian Cancer”. Co-Principal Investigator, with Dr. Andrew Morris, Lineberger Cancer Center, University of North Carolina; NIH R01 CA96496-01 $200,000, 2001

3. American Cancer Society Career Development Award, University of North Carolina, Chapel Hill; $90,000 1994-1997

Publications
Bae Jump V, Baker M, Bauer, Van Le L. Cytologic Evaluation Correlates Poorly with Histologic Diagnosis of Vulvar Neoplasias. Accepted Journal of Lower Genital Tract Diseases, 2006.

Rinas AC, Mittman BW, Van Le L, Hartmann K, Cayless J, Singh HK. Split-sample
analysis of discarded cells from liquid-based pap smear sampling devices. Acta Cytologica 2006; 50: 55-62.

Skinner E, Boruta DM, Gehrig PA, Boggess JF, Fowler WC, Van Le L. Consolidation therapy with weekly paclitaxel infusion in ovarian cancer: An extended follow-up.Gynecol Oncol 2005; 98:59-62.

Gehrig PA, Bae-Jump V, Boggess JF, Groben PA, Fowler WC, Van Le L. Association between uterine serous carcinoma and breast cancer. Gynecologic Oncology, 2004, 94: 208-211.

Boruta DM, Gehrig PA, Boggess JF, Groben PA, Bae-Jump V, Fower Jr WC, Van Le L. Uterine serous and grade 3 endometrioid carcinomas: Is there a survival difference? Cancer, 2004, 101: 2214-21.

Gehrig PA, Morris D, Van Le L. Uterine Papillary Serous Carcinoma: A Comparison of Therapy for Advanced Stage Disease. Int J Gynecol Cancer 2004;14:515-520.

Livasy C, Van Le L. Negative cervical LEEP after biopsy-confirmed HSIL: incidence, clinical significance and histology features. Obstetrics and Gynecology 2004, 104:250-4.

Skinner E, Gehrig PA, Van Le L. High-grade squamous intra-epithelial lesions (HSIL): Abbreviating post-treatment surveillance. Obstet Gynecol 2004; 103:488-92.

Blatt J, Van Le L, Weiner T, Sailer S. Ovarian carcinoma in an adolescent with transgenerational exposure to diethylstilbestrol. J of Ped Hem Onc 2003, 25:635-6.

Gehrig PA, Bae-Jump VL, , Boggess JF, Groben PA, Fowler Jr WC, Van Le L. Association between uterine serous carcinoma and breast cancer. Gynecologic Oncology, 2004, 94:208-211.

Fowler WC, Van Le L. Gemcitabine as a single-agent treatment for ovarian cancer. Gynecol Oncol 2003;90:S21-S23.

Gehrig PA, Van Le L, W Fowler. The role of omentectomy during the surgical staging of uterine papillary serous carcinoma. Int J Gynecol Cancer 2003;13:212-15.

Fowler WC Jr, Van Le L: Gemcitabine as a single-agent treatment for ovarian cancer. Gynecologic Oncology. 2003, 90, S21-S23.

Gehrig PA, Olilla D, Boggess J, Groben PA, Van Le L. Advanced appendiceal cancer imitating ovarian cancer. Int J Gynecol Cancer 2002:12:768-72.

Rose PG, Brunetto VL, Van Le L, Bell J, Walker JL, Lee RB. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol 2000;78:212-216.

Miller DS, Blessing JA, Kilgore LC, Mannel R, Van Le L. A phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: A Gynecologic Oncology Group Study. American Journal of Clinical Oncology 2000;22:355-357.

Gehrig PA, Van Le L. The prognostic value and clinical utility of estrogen and progesterone receptors in endometrial carcinoma. Primary Care Update for Ob/Gyns, 2000;7:55-59. Modesitt SC, Groben P, Walton LA, Fowler WC, Van Le L.

Expression of Ki-67 in vulvar carcinoma and vulvar epithelial neoplasia III: correlation with clinical prognostic factors. Gynecol Oncol 2000;76:51-55.

Gehrig PA, Van Le L, Olatidoye B, Geradts, J. Estrogen receptor status by immunohistochemistry as a predictor of recurrence in stage 1 endomoetrial carcinoma. Cancer, 1999;86:2083-2089.

Judson P, He XP, Cance W, Van Le L. Overexpression of FAK in ovarian cancers. Cancer, 1999;86:1551-1556. Modesitt S, Waters A, Walton LA, Fowler, WC, Van Le L. Vulvar intraepithelial neoplasia III: Occult cancer and the impact of margin status on recurrence. Obstetrics and Gynecology, 1998;92:962-6.

Judson P, Van Le L. Familial breast and ovarian cancer: the role of the BRCA genes. Primary Care Update for Ob/Gyn. 1998;5: 140-143.

Van Le L, and Fowler WC. Saline breast implant to protect the pelvic floor after pelvic exenteration. Gynecol Oncol 1997;65:188-91.

Judson P, Van Le L. Flow Cytometry for Obstetricians and Gynecologists. Primary Care Update for Ob/Gyn 1997;4:87-91. Buckley S, Tritz D, Van Le L, et al. Lymph node metastases and prognosis in patients with stage IA2 cervical cancer. Gynecol Oncol 1996;63:4-9.

Rinehart, CA, Xu L, Van Le L, Kaufman DG. Diethylstilbestrol-induced immortalization of human endometrial cells: alterations in p53 and estrogen receptor. Molecular Carcinogenesis 1995; 15:115-123.

DeMars LR, Van Le L, Huang I, Fowler WC. Primary non-clear-cell adenocarcinoma of the vagina in older DES-exposed women. Gynecol Oncol 1995; 58:389-392.

Van Le L, Walton, LA, Moore DH, Fowler WC, Fakhry S, Rutledge R. Use of the APACHE II scoring system to determine mortality of gynecologic oncology patients in the intensive care unit. Obstet Gynecol 1995; 85:53-6.

Van Le L, Parker LA, DeMars, LR, MacKoul P, Fowler WC. Pleural effusions: Outpatient management with pigtail catheter chest tubes. Gynecol Oncol 1994;54:215-7.

Jaffe GJ, Richmond A, Van Le L, Shattuck R, Chang QC, Wong F, Roberts W. Expression of three forms of melanoma growth stimulating activity (MGSA)/gro in human retinal epithelial cells. Invest Ophthalmol Vis Sci 1993;34: 2776-85.

Van Le L, Stoerker J, Rinehart CA, Fowler WC. H-ras codon 12 mutations in cervical dysplasias. Gynecol Oncol 1993; 49:181-4.

Van Le L, Broekhuizen FF, Steele R, Behar M, Samter T. Acetic acid visualization of cervical dysplasias. Obstet Gynecol 1993; 81:293-5.

Jaffe G, Van Le L, Valea F et al. Expression of IL-1a and IL-1b and an IL-1 receptor antagonist in human retinal pigment epithelial cells. Exp Eye Res 1992;55:325-335.

Van Le L, Oh ST, Anners JA, Rinehart CA, Halme J. Interleukin-1b inhibits growth and proliferation of normal human endometrial stroma cells. Obstet Gynecol 1992;80:405-9.

Van Le L, Novotny D, Dotters DJ. Distinguishing tubal metaplasia from endocervical dysplasia on cervical papanicolaou smears. Obstet Gynecol 1991;78:974-5.

Van Le L, Pizzutti D, Greenberg M, Reid R. Vaginal 5-FU therapy: accidental use in pregnancy. J Reprod Med 1991;36:872-4.

Van Le L, Haskill S, Jaffe G, Fowler WC. Expression of interleukin-1 and its receptor antagonists in endometrial cancer. Gynecol Oncol 1991; 42:161-4.

Haskill S, Martin G, Van Le, L, Peace A. cDNA cloning of a novel intracellular form of the iL-lra associated with epithelium. Proc Natl Acad Sci U.S.A. 1991; 88:3681-5.

Stern JS, Majors C, and Van Le L. Preventing cervical conization by achieving satisfactory colposcopy with hygroscopic cervical dilators. Am J Obstet Gynecol 1990;163:176-7.

Van Le L, Podrasky A. Computed Tomographic and Ultrasonogrophic Findings in Women with Acute Fatty Liver of Pregnancy. J Reprod Med 1990;35:815-7.

Van Le L, Darney P. Successful pregnancy outcome after cervical dilation with multiple laminaria in preparation for elective abortion: a report of two cases. Am J Obstet Gynecol 1987;156:612.

McLeod R, Van Le L, Remington JS: Toxoplasma gondii: Lymphocyte function during acute infection in mice. Experimental Parasitology 1982;54:55.